neuroClues

🔥 We are so excited to share with you that NeuroClues™ is amongst the very few promising start-ups (<8%) awarded the prestigious EIC accelerator funding! We are now ready to move to the next phase: demonstrating the clinical use of neuroClues in the diagnosis of Parkinson’s Disease and supporting its early commercial roll-out!   🇪🇺 The European Innovation Council (EIC) is the EU Commission's flagship innovation program to identify, develop and scale up breakthrough technologies and game-changing innovations. The EIC Accelerator provides substantial financial support with grant funding and direct equity investments managed by the EIC Fund. 🚀 This recognition confirms our ambition for NeuroClues™ to become the brain’s stethoscope, supporting 10M patients by 2030. Congratulations to the whole team! We’re on the right track to fulfill our mission, with the support from Institut du Cerveau – Paris Brain Institute and iPEPS The Healthtech Hub. More info on the press release: https://lnkd.in/g5pZPmAH European Innovation Council and SMEs Executive Agency (EISMEA) invest.bw Graph Ventures Pierre de Waha L'Echo Antoine Pouppez Pierre Daye Pierre Pouget Jean-Baptiste de Harenne Marie Dautrebande Camille Verriest Frédérique Boël Florian Guyot Mark Turcksin Alejandra Mejia Philippe Domineaux Valérie Roels Caroline Van den Eynde @Tym Poitou Bao Nguyen Simon Gerard   #EUeic #eicAccelerator #neuroscience #innovationinhealthcare #capitalventure #funding #scaling

🚀 Exciting times ahead as we gear up for Ghent Slush'D, the largest gathering of founders and investors in Belgium! 🇧🇪This incredible event will bring together innovators from Flanders, Brussels, and Wallonia to share insights, connect with over 150+ investors, and help put Belgian startups on the global stage. 🌍 🤝At neuroClues, we’re excited to be part of this journey alongside Wallonia Export & Investment Agency, whose support helps Wallonian startups like ours expand and thrive. Collaboration drives our success, and we’re looking forward to achieve great things together. ❓What we do:  The eyes are a window to the brain, offering valuable insights into neurological health.  neuroClues aims to provide neurologists with objective, quantifiable data, integrating the wealth of eye-tracking directly into their consultation. In other words, we aim to become the brain’s stethoscope.  👀Curious to learn more? Connect with our CEO - Antoine Pouppez, and discover how eye movements can transform neurological diagnosis. See you in beautiful Ghent! #Biomarkers #neuroscience #eyetracking #ghentslushd #industryleaders #GhentSlushD #startup * neuroClues is in research & development phase and its commercial availability is pending regulatory approval.  

👀"The eyes might just be the most underrated superheroes we have," said Anca Petre, host of the Science for Care podcast. 🎙️In the latest episode, co-founders Pierre Pouget and Antoine Pouppez discuss the critical role of eye tracking in neurology and how neuroClues could bring innovation to the field. 🥼 Today, neurologists rely on clinical observation during consultations to assess patients, but they often lack quantitative data within the short time frame of a 20-minute consultation. neuroClues seeks to offer objective measurements to complement these observations, aiming to add value to neurologists’ existing expertise, all without extending the consultation time or avoiding complementary exams. 🎧 Listen to the podcast and learn more about the fascinating perspectives opened by the clinical use of eye tracking! ⚡️ If you're interested in learning how this technology could further support neurological diagnosis, please reach out. We'd love to share more insights! HealthTech For Care #biomarkers #neuroscience #eyetracking  #neurology * neuroClues is in research & development phase and its commercial availability is pending regulatory approval.

📢 Exciting insights from Marie VIDAILHET's recent review on the often-overlooked visual impairments in Parkinson's Disease (PD) and their potential as biomarkers for early diagnosis and disease progression! Key findings: 🔑Saccades and anti-saccades are examined as potential biomarkers for assessing motor and cognitive burdens in #PD. Abnormalities in these eye movements correlate with disease severity and can predict future complications such as freezing of gait. 🔑Eye movement analysis can aid in distinguishing between PD and other parkinsonian syndromes like Progressive Supranuclear Palsy (#PSP) and Multiple System Atrophy (#MSA).  🔑Convergence insufficiency (CI) is prevalent in PD patients, affecting their ability to focus on near objects and leading to difficulties in tasks like reading 🔑Optical coherence tomography (OCT) is highlighted as a valuable tool for detecting early structural changes in the retina, serving as a potential early diagnostic marker for PD. ⚡️The review emphasizes integrating eye movement analysis into clinical practice to improve diagnostic accuracy and monitor disease progression. Ocular assessments provide valuable insights into PD that extend beyond traditional motor symptoms. #biomarkers #neuroscience #eyetracking

📣We are thrilled to announce that neuroClues is one of the 10 finalists in the Health Tech Challengers, under the Disruptive Diagnosis track! 🌐 Health Tech Challengers is a prestigious platform for digital health startups, giving them the opportunity to showcase how they are shaping the future of healthcare. Out of 10 finalists in each of the 8 digital health tracks, one winner will be chosen based on their pitch, and we are honored to stand alongside such innovative companies. 💥 How is neuroClues disruptive?  Eye movements are the window into the brain. Long before clinical symptoms appear, eye movements can offer clues about neurological health. By providing an objective, quantifiable, and quick way to measure ocular biomarkers, neuroClues could empower clinicians to make more accurate diagnoses—potentially reducing the need for costly and time-consuming tests. 🎯 In essence, we aim to be the stethoscope for the brain. 🙌 A big thank you to Health Tech Challengers and the panel of experts for this recognition. Congratulations to all the other finalists—we’re excited to hear your pitches and learn how your innovations are transforming healthcare! 🚀 And of course, Antoine Pouppez, we can't wait to see you pitch at Health Tech Forward in December, you've got this! #biomarkers #neuroscience #eyetracking * neuroClues is in research & development phase and its commercial availability is pending regulatory approval.

🧠 Today is #WorldMSADay, a crucial time to raise awareness about a disease with a misdiagnosis rate as high as 20%. ⚕️ Multiple System Atrophy (MSA) is a progressive neurodegenerative disorder affecting the central and autonomic nervous systems. It causes movement difficulties, balance and coordination issues, and autonomic dysfunction. The disease progresses rapidly, leading to increased disability and often necessitating walking aids. 👁️ A crucial aspect of #MSA is eye movement dysfunction, caused by degeneration in brainstem structures that control eye movements. Diagnosing MSA is particularly challenging: 🩺 MSA is categorized as an atypical parkinsonian syndrome due to its resemblance to Parkinson's disease. It’s frequently misdiagnosed as Parkinson's or progressive supranuclear palsy, complicating research efforts across all three conditions. 🩺MSA presents in two distinct forms: MSA-P (parkinsonian type) and MSA-C (cerebellar type), each with unique clinical features, progression rates, and treatment responses. These 2 forms are hard to distinguish. New research highlights the potential of eye movement monitoring to revolutionize MSA diagnosis and care. It offers the ability to: 🔬Improve diagnostic accuracy, reducing the need for unnecessary invasive tests 🔬Enhance patient selection for clinical trials, ultimately speeding up the development of new treatments 💪Today, let's raise awareness and work towards better outcomes for those living with MSA. Bas Bloem Marcel Verbeek Bart van de Warrenburg Multiple System Atrophy Trust Mission MSA International Parkinson and Movement Disorder Society National Organization for Rare Disorders #biomarkers #neuroscience #eyetracking

🎯 Rencontrez Tymothée Poitou, notre conseiller clinique, à la SOFMER du 2 au 4 octobre ! La Société Française de Médecine Physique et de Réadaptation (#SOFMER) est le rendez-vous incontournable pour découvrir les dernières avancées en rééducation et médecine physique. 💡 Tymothée Poitou y présentera "Vers une nouvelle évaluation quantifiée de l’hémiparésie aiguë post-AVC : le score early Composite XA", un outil qui permet de mesurer et suivre la faiblesse musculaire post-AVC, améliorant ainsi la rééducation des patients. 👀 Mais ce n’est pas tout ! Tymothée partage également notre intérêt pour les mouvements oculaires, essentiels dans le diagnostic et le suivi des maladies neurologiques. N’hésitez pas à le solliciter si ce sujet vous passionne – il sera ravi d’en discuter avec vous !  #biomarkers #neuroscience #eyetracking #SOFMER24

🏎️ We’re not slowing down! Next stop: Chicago, for the Society for Neuroscience's annual meeting. 🧠Neuroscience is where it all began for our co-founders, Pierre Daye and Pierre Pouget. Their dedication to the field sparked years of research, particularly focusing on eye movements—a passion that became the foundation of our work. 🤝This event is meaningful for us, as we’re connecting with fellow neuroscientists who recognize the potential of eye movements research. 💪 We’re back with another poster on Sunday, October 6th! Don’t miss ‘Pupillometry and Geometrical Characteristics Parameters during Visual and Oculomotor Tasks’ by our co-founders Pierre Daye and Pierre Pouget. It explores the latest research and the exciting opportunities for innovation in developing more advanced pupillometry metrics. 🙌Swing by booth #158, where we'll showcase our efforts to bring the wealth of eye tracking research to the clinical practice. Our goal? Offer a device which allows this translation from research to clinic through a simple workflow and uncompromised technical capabilities.  #neuroscience #biomarkers #eyetracking * neuroClues is in research & development phase and its commercial availability is pending regulatory approval.

💜 On September 21st, we recognized World Alzheimer’s Day—a vital occasion to raise awareness and share experiences related to this challenging condition. It’s a time to reflect on the lives of those affected by Alzheimer’s and to honor the dedication of healthcare practitioners who tirelessly support patients and their families. 🥼 We also acknowledge the researchers who are passionately working to uncover effective treatments for this complex disease. The prevalence of all-cause dementia is projected to rise from 50 million in 2010 to an alarming 153 million by 2050 worldwide. As a company dedicated to medical innovation, we recognize the growing challenge that Alzheimer’s presents and are inspired to take action. ✨At neuroClues, we are dedicated to making a meaningful impact. Our goal is to empower neurologists, enabling them to make informed decisions that lead to earlier and more accurate diagnoses for patients. Together, let’s work towards improving the journey for those affected by Alzheimer’s. Alzheimer's Society Alzheimer's Association® Alzheimer's Foundation of America Alzheimer's Disease International Alzheimer's Drug Discovery Foundation American Brain Foundation BrightFocus Foundation Alzheimer's Research UK #biomarkers #eyetracking #neuroscience #EndAlz #AlzheimersAwareness #GoPurple  * neuroClues is in research & development phase and its commercial availability is pending regulatory approval. 

🧳 We’re gearing up for the 2024 International Parkinson and Movement Disorder Society meeting! 🥼This event brings together clinicians, researchers, and industry leaders to advance the treatment of movement disorders and support those affected by Parkinson’s and similar conditions. How could eye-tracking benefit those with Parkinson’s and other movement disorders? 🔍Early detection: Eye movement abnormalities often emerge before clinical symptoms, and having the right tool to detect these early changes could provide clues to faster diagnosis and treatment. 🩺Accurate diagnosis: Eye movement analysis could help distinguish Parkinson’s from other movement disorders, preventing misdiagnosis and unnecessary treatments that could worsen the condition. 📝Treatment monitoring: By tracking eye movement improvements, practitioners could assess treatment effectiveness over time. 👀 Don't miss Pierre Daye’s poster presentation on Saturday, Sept 28th, presenting promising preliminary evidence for a potential pre-clinical Parkinson's test based on eye movements. While more studies are needed to confirm these findings, we're excited to share this breakthrough ! 👩🏫Our team of experts is ready to show you how the right tool for quantifying eye movements can be a game-changer in your consultations. Swing by booth #217 and discover the potential of eye movement analysis firsthand! #biomarkers #eyetracking #neuroscience #MDS #MDS24 #MDSCongress * neuroClues is in research & development phase and its commercial availability is pending regulatory approval.